Trial Profile
LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs LEO 27847 (Primary)
- Indications Kidney disorders; Secondary hyperparathyroidism
- Focus Adverse reactions; First in man
- Sponsors LEO Pharma
- 05 Apr 2016 New trial record